Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.22.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenue $ 8 $ 118
Cost of goods sold 0 99
Gross profit 8 19
Operating expenses:    
Research and development 1,617 1,266
General and administrative 6,401 7,271
Depreciation and amortization 55 42
Total operating expenses 8,073 8,579
Loss from operations (8,065) (8,560)
Other income (expense):    
Interest income, net 0 1
Loss before income taxes (8,065) (8,559)
Income taxes (benefit) 0 0
Net loss (8,065) (8,559)
Non-controlling interest 102 240
Net loss attributable to BioSig Technologies, Inc. (7,963) (8,319)
Preferred stock dividend (2) (2)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS $ (7,965) $ (8,321)
Net loss per common share, basic and diluted (in Dollars per share) $ (0.22) $ (0.26)
Weighted average number of common shares outstanding, basic and diluted (in Shares) 35,997,298 31,584,142
Product [Member]    
Revenue $ 0 $ 115
Service [Member]    
Revenue $ 8 $ 3